References
- Howies CM, Loumaye E, Giroud D, et al. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum Reprod 1994; 9: 424–30
- Out HJ, Driessen SGA, Bernadette MJL, et al. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil Steril 1997; 68: 138–42
- Bergh C, Howies CM, Borg K, et al. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod 1997; 12: 2133–9
- Jacob S, Drudy L, Conroy R, Harrison RF. Outcome from consecutive in-vitro fertilization/intracytoplasmic sperm injection attempts in the final group treated with urinary gonadotropins and in the first group treated with recombinant follicle stimulating hormone. Hum Reprod 1998; 13: 1783–7
- Meniru GI. Is Puregon a ‘good’ or ‘super’ drug?. Hum Reprod 1999; 14: 1409–11
- Balen HA, Hayden J, Rutherford AJ. Clinical efficacy of recombinant gonadotrophins. Hum Reprod 1999; 14: 1411–17
- Felberbaum RE, Ludwig M, Diedrich K. Are we on the verge of a new era in ART?. Hum Reprod 1998; 13: 1778–80
- Biffoni M, Battaglia A, Borelli F, et al. Allergenic potential of gonadotrophic preparations in experimental animals: relevance of purity. Hum Reprod 1994; 9: 1835–6